Immunic, Inc.
IMUX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | 0.10 | -0.06 |
| FCF Yield | -84.88% | -107.04% | -146.49% | -36.80% |
| EV / EBITDA | -0.67 | -0.21 | 0.70 | -1.53 |
| Quality | ||||
| ROIC | -504.56% | -327.85% | -103.68% | -71.55% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.76 | 0.54 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.49% | -9.05% | 21.66% | -80.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 0.46 | 1.22 | 0.94 |
| Interest Coverage | 0.00 | 0.00 | -114.78 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |